Cyclerion Therapeutics Inc
Research Cyclerion Therapeutics Inc (CYCN) on Bullrun: market cap USD 17.03M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCYCN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 17.03M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 1.76M
- Free cash flow-USD 1.43M
Valuation Snapshot
latest market cap is USD 17.03M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.07M | -USD 3.53M | -USD 3.31M | n/a | -1.11 | USD 3.24M | n/a | USD 9.09M |
| FY2024 | USD 2.00M | -USD 3.06M | -USD 4.33M | n/a | -1.21 | USD 3.23M | n/a | USD 8.85M |
| FY2023 | USD 0 | -USD 5.26M | n/a | n/a | -2.25 | USD 7.57M | n/a | USD 11.29M |
| FY2022 | USD 297.00K | -USD 44.08M | -USD 40.61M | n/a | -20.28 | USD 13.38M | USD 3.50M | USD 10.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 17.03M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.85M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.20M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 8.19M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 28.53M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 74.67M | n/a | n/a | n/a |
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cyclerion Therapeutics Inc's market cap?
Cyclerion Therapeutics Inc's market capitalization is USD 17.03M.
What does Cyclerion Therapeutics Inc do?
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease.